Medical Care
Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Research Report 2025
- Mar 13, 25
- ID: 129821
- Pages: 100
- Figures: 100
- Views: 53
The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO was valued at US$ 3863 million in the year 2024 and is projected to reach a revised size of US$ 12840 million by 2031, growing at a CAGR of 19.0% during the forecast period.
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
North American market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antibody-drug Conjugates (ADCs) CMO and CDMO include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugates (ADCs) CMO and CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugates (ADCs) CMO and CDMO.
The Antibody-drug Conjugates (ADCs) CMO and CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugates (ADCs) CMO and CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-drug Conjugates (ADCs) CMO and CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Segment by Type
Cleavable linkers
Non-cleavable linkers
Segment by Application
Solid Tumors
Hematological Malignanciesncies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugates (ADCs) CMO and CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
North American market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antibody-drug Conjugates (ADCs) CMO and CDMO include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugates (ADCs) CMO and CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugates (ADCs) CMO and CDMO.
The Antibody-drug Conjugates (ADCs) CMO and CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugates (ADCs) CMO and CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-drug Conjugates (ADCs) CMO and CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Segment by Type
Cleavable linkers
Non-cleavable linkers
Segment by Application
Solid Tumors
Hematological Malignanciesncies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugates (ADCs) CMO and CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cleavable linkers
1.2.3 Non-cleavable linkers
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumors
1.3.3 Hematological Malignanciesncies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Perspective (2020-2031)
2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Growth Trends by Region
2.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Region (2020-2025)
2.2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031)
2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Dynamics
2.3.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Trends
2.3.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers
2.3.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
2.3.4 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue
3.1.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue (2020-2025)
3.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue
3.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024
3.5 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO Head office and Area Served
3.6 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application
3.7 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Type
4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Type (2020-2025)
4.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031)
5 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Application
5.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Application (2020-2025)
5.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
6.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
6.4 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
7.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
7.4 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
8.2 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
9.2 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
9.4 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
10.2 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Details
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.1.4 Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.1.5 Lonza Group Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Details
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.2.4 Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.2.5 Merck KGaA Recent Development
11.3 WuXi XDC
11.3.1 WuXi XDC Company Details
11.3.2 WuXi XDC Business Overview
11.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.3.4 WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.3.5 WuXi XDC Recent Development
11.4 Abbvie
11.4.1 Abbvie Company Details
11.4.2 Abbvie Business Overview
11.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.4.4 Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.4.5 Abbvie Recent Development
11.5 Piramal Pharma Solutions
11.5.1 Piramal Pharma Solutions Company Details
11.5.2 Piramal Pharma Solutions Business Overview
11.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.5.4 Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.5.5 Piramal Pharma Solutions Recent Development
11.6 Catalent
11.6.1 Catalent Company Details
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.6.4 Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.6.5 Catalent Recent Development
11.7 Sterling Pharma Solutions
11.7.1 Sterling Pharma Solutions Company Details
11.7.2 Sterling Pharma Solutions Business Overview
11.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.7.4 Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.7.5 Sterling Pharma Solutions Recent Development
11.8 Axplora
11.8.1 Axplora Company Details
11.8.2 Axplora Business Overview
11.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.8.4 Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.8.5 Axplora Recent Development
11.9 Aji Bio-Pharma
11.9.1 Aji Bio-Pharma Company Details
11.9.2 Aji Bio-Pharma Business Overview
11.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.9.4 Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.9.5 Aji Bio-Pharma Recent Development
11.10 BSP Pharmaceuticals
11.10.1 BSP Pharmaceuticals Company Details
11.10.2 BSP Pharmaceuticals Business Overview
11.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.10.4 BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.10.5 BSP Pharmaceuticals Recent Development
11.11 Cerbios-Pharma
11.11.1 Cerbios-Pharma Company Details
11.11.2 Cerbios-Pharma Business Overview
11.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.11.4 Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.11.5 Cerbios-Pharma Recent Development
11.12 Goodwin Biotechnology
11.12.1 Goodwin Biotechnology Company Details
11.12.2 Goodwin Biotechnology Business Overview
11.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.12.4 Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.12.5 Goodwin Biotechnology Recent Development
11.13 TOT Biopharm
11.13.1 TOT Biopharm Company Details
11.13.2 TOT Biopharm Business Overview
11.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.13.4 TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.13.5 TOT Biopharm Recent Development
11.14 Huadong Medicine
11.14.1 Huadong Medicine Company Details
11.14.2 Huadong Medicine Business Overview
11.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.14.4 Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.14.5 Huadong Medicine Recent Development
11.15 Innovent Biologics
11.15.1 Innovent Biologics Company Details
11.15.2 Innovent Biologics Business Overview
11.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.15.4 Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.15.5 Innovent Biologics Recent Development
11.16 Shanghai Henlius Biotech
11.16.1 Shanghai Henlius Biotech Company Details
11.16.2 Shanghai Henlius Biotech Business Overview
11.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.16.4 Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.16.5 Shanghai Henlius Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cleavable linkers
1.2.3 Non-cleavable linkers
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumors
1.3.3 Hematological Malignanciesncies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Perspective (2020-2031)
2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Growth Trends by Region
2.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Region (2020-2025)
2.2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031)
2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Dynamics
2.3.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Trends
2.3.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers
2.3.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
2.3.4 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue
3.1.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue (2020-2025)
3.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue
3.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024
3.5 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO Head office and Area Served
3.6 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application
3.7 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Type
4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Type (2020-2025)
4.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031)
5 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Application
5.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Application (2020-2025)
5.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
6.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
6.4 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
7.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
7.4 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
8.2 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
9.2 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
9.4 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
10.2 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Details
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.1.4 Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.1.5 Lonza Group Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Details
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.2.4 Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.2.5 Merck KGaA Recent Development
11.3 WuXi XDC
11.3.1 WuXi XDC Company Details
11.3.2 WuXi XDC Business Overview
11.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.3.4 WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.3.5 WuXi XDC Recent Development
11.4 Abbvie
11.4.1 Abbvie Company Details
11.4.2 Abbvie Business Overview
11.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.4.4 Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.4.5 Abbvie Recent Development
11.5 Piramal Pharma Solutions
11.5.1 Piramal Pharma Solutions Company Details
11.5.2 Piramal Pharma Solutions Business Overview
11.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.5.4 Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.5.5 Piramal Pharma Solutions Recent Development
11.6 Catalent
11.6.1 Catalent Company Details
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.6.4 Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.6.5 Catalent Recent Development
11.7 Sterling Pharma Solutions
11.7.1 Sterling Pharma Solutions Company Details
11.7.2 Sterling Pharma Solutions Business Overview
11.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.7.4 Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.7.5 Sterling Pharma Solutions Recent Development
11.8 Axplora
11.8.1 Axplora Company Details
11.8.2 Axplora Business Overview
11.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.8.4 Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.8.5 Axplora Recent Development
11.9 Aji Bio-Pharma
11.9.1 Aji Bio-Pharma Company Details
11.9.2 Aji Bio-Pharma Business Overview
11.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.9.4 Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.9.5 Aji Bio-Pharma Recent Development
11.10 BSP Pharmaceuticals
11.10.1 BSP Pharmaceuticals Company Details
11.10.2 BSP Pharmaceuticals Business Overview
11.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.10.4 BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.10.5 BSP Pharmaceuticals Recent Development
11.11 Cerbios-Pharma
11.11.1 Cerbios-Pharma Company Details
11.11.2 Cerbios-Pharma Business Overview
11.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.11.4 Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.11.5 Cerbios-Pharma Recent Development
11.12 Goodwin Biotechnology
11.12.1 Goodwin Biotechnology Company Details
11.12.2 Goodwin Biotechnology Business Overview
11.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.12.4 Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.12.5 Goodwin Biotechnology Recent Development
11.13 TOT Biopharm
11.13.1 TOT Biopharm Company Details
11.13.2 TOT Biopharm Business Overview
11.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.13.4 TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.13.5 TOT Biopharm Recent Development
11.14 Huadong Medicine
11.14.1 Huadong Medicine Company Details
11.14.2 Huadong Medicine Business Overview
11.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.14.4 Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.14.5 Huadong Medicine Recent Development
11.15 Innovent Biologics
11.15.1 Innovent Biologics Company Details
11.15.2 Innovent Biologics Business Overview
11.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.15.4 Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.15.5 Innovent Biologics Recent Development
11.16 Shanghai Henlius Biotech
11.16.1 Shanghai Henlius Biotech Company Details
11.16.2 Shanghai Henlius Biotech Business Overview
11.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction
11.16.4 Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
11.16.5 Shanghai Henlius Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cleavable linkers
Table 3. Key Players of Non-cleavable linkers
Table 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2025)
Table 8. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2026-2031)
Table 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Trends
Table 11. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers
Table 12. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
Table 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints
Table 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players (2020-2025)
Table 16. Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO as of 2024)
Table 17. Ranking of Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Headquarters and Area Served
Table 20. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application
Table 21. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2020-2025)
Table 25. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2026-2031)
Table 27. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2020-2025)
Table 29. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2026-2031)
Table 31. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Group Company Details
Table 47. Lonza Group Business Overview
Table 48. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 49. Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 50. Lonza Group Recent Development
Table 51. Merck KGaA Company Details
Table 52. Merck KGaA Business Overview
Table 53. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 54. Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 55. Merck KGaA Recent Development
Table 56. WuXi XDC Company Details
Table 57. WuXi XDC Business Overview
Table 58. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 59. WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 60. WuXi XDC Recent Development
Table 61. Abbvie Company Details
Table 62. Abbvie Business Overview
Table 63. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 64. Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 65. Abbvie Recent Development
Table 66. Piramal Pharma Solutions Company Details
Table 67. Piramal Pharma Solutions Business Overview
Table 68. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 69. Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 70. Piramal Pharma Solutions Recent Development
Table 71. Catalent Company Details
Table 72. Catalent Business Overview
Table 73. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 74. Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 75. Catalent Recent Development
Table 76. Sterling Pharma Solutions Company Details
Table 77. Sterling Pharma Solutions Business Overview
Table 78. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 79. Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 80. Sterling Pharma Solutions Recent Development
Table 81. Axplora Company Details
Table 82. Axplora Business Overview
Table 83. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 84. Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 85. Axplora Recent Development
Table 86. Aji Bio-Pharma Company Details
Table 87. Aji Bio-Pharma Business Overview
Table 88. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 89. Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 90. Aji Bio-Pharma Recent Development
Table 91. BSP Pharmaceuticals Company Details
Table 92. BSP Pharmaceuticals Business Overview
Table 93. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 94. BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 95. BSP Pharmaceuticals Recent Development
Table 96. Cerbios-Pharma Company Details
Table 97. Cerbios-Pharma Business Overview
Table 98. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 99. Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 100. Cerbios-Pharma Recent Development
Table 101. Goodwin Biotechnology Company Details
Table 102. Goodwin Biotechnology Business Overview
Table 103. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 104. Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 105. Goodwin Biotechnology Recent Development
Table 106. TOT Biopharm Company Details
Table 107. TOT Biopharm Business Overview
Table 108. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 109. TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 110. TOT Biopharm Recent Development
Table 111. Huadong Medicine Company Details
Table 112. Huadong Medicine Business Overview
Table 113. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 114. Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 115. Huadong Medicine Recent Development
Table 116. Innovent Biologics Company Details
Table 117. Innovent Biologics Business Overview
Table 118. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 119. Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 120. Innovent Biologics Recent Development
Table 121. Shanghai Henlius Biotech Company Details
Table 122. Shanghai Henlius Biotech Business Overview
Table 123. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 124. Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 125. Shanghai Henlius Biotech Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
Table 129. Authors List of This Report
List of Figures
Figure 1. Antibody-drug Conjugates (ADCs) CMO and CDMO Picture
Figure 2. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type: 2024 VS 2031
Figure 4. Cleavable linkers Features
Figure 5. Non-cleavable linkers Features
Figure 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application: 2024 VS 2031
Figure 8. Solid Tumors Case Studies
Figure 9. Hematological Malignanciesncies Case Studies
Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Report Years Considered
Figure 11. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region: 2024 VS 2031
Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players in 2024
Figure 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024
Figure 17. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 19. United States Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 23. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2031)
Figure 31. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 39. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 43. Turkey Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Lonza Group Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 47. Merck KGaA Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 48. WuXi XDC Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 49. Abbvie Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 50. Piramal Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 51. Catalent Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 52. Sterling Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 53. Axplora Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 54. Aji Bio-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 55. BSP Pharmaceuticals Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 56. Cerbios-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 57. Goodwin Biotechnology Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 58. TOT Biopharm Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 59. Huadong Medicine Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 60. Innovent Biologics Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 61. Shanghai Henlius Biotech Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cleavable linkers
Table 3. Key Players of Non-cleavable linkers
Table 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2025)
Table 8. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2026-2031)
Table 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Trends
Table 11. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers
Table 12. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
Table 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints
Table 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players (2020-2025)
Table 16. Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO as of 2024)
Table 17. Ranking of Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Headquarters and Area Served
Table 20. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application
Table 21. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2020-2025)
Table 25. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2026-2031)
Table 27. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2020-2025)
Table 29. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2026-2031)
Table 31. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Group Company Details
Table 47. Lonza Group Business Overview
Table 48. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 49. Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 50. Lonza Group Recent Development
Table 51. Merck KGaA Company Details
Table 52. Merck KGaA Business Overview
Table 53. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 54. Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 55. Merck KGaA Recent Development
Table 56. WuXi XDC Company Details
Table 57. WuXi XDC Business Overview
Table 58. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 59. WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 60. WuXi XDC Recent Development
Table 61. Abbvie Company Details
Table 62. Abbvie Business Overview
Table 63. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 64. Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 65. Abbvie Recent Development
Table 66. Piramal Pharma Solutions Company Details
Table 67. Piramal Pharma Solutions Business Overview
Table 68. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 69. Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 70. Piramal Pharma Solutions Recent Development
Table 71. Catalent Company Details
Table 72. Catalent Business Overview
Table 73. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 74. Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 75. Catalent Recent Development
Table 76. Sterling Pharma Solutions Company Details
Table 77. Sterling Pharma Solutions Business Overview
Table 78. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 79. Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 80. Sterling Pharma Solutions Recent Development
Table 81. Axplora Company Details
Table 82. Axplora Business Overview
Table 83. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 84. Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 85. Axplora Recent Development
Table 86. Aji Bio-Pharma Company Details
Table 87. Aji Bio-Pharma Business Overview
Table 88. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 89. Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 90. Aji Bio-Pharma Recent Development
Table 91. BSP Pharmaceuticals Company Details
Table 92. BSP Pharmaceuticals Business Overview
Table 93. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 94. BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 95. BSP Pharmaceuticals Recent Development
Table 96. Cerbios-Pharma Company Details
Table 97. Cerbios-Pharma Business Overview
Table 98. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 99. Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 100. Cerbios-Pharma Recent Development
Table 101. Goodwin Biotechnology Company Details
Table 102. Goodwin Biotechnology Business Overview
Table 103. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 104. Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 105. Goodwin Biotechnology Recent Development
Table 106. TOT Biopharm Company Details
Table 107. TOT Biopharm Business Overview
Table 108. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 109. TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 110. TOT Biopharm Recent Development
Table 111. Huadong Medicine Company Details
Table 112. Huadong Medicine Business Overview
Table 113. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 114. Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 115. Huadong Medicine Recent Development
Table 116. Innovent Biologics Company Details
Table 117. Innovent Biologics Business Overview
Table 118. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 119. Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 120. Innovent Biologics Recent Development
Table 121. Shanghai Henlius Biotech Company Details
Table 122. Shanghai Henlius Biotech Business Overview
Table 123. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product
Table 124. Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)
Table 125. Shanghai Henlius Biotech Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
Table 129. Authors List of This Report
List of Figures
Figure 1. Antibody-drug Conjugates (ADCs) CMO and CDMO Picture
Figure 2. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type: 2024 VS 2031
Figure 4. Cleavable linkers Features
Figure 5. Non-cleavable linkers Features
Figure 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application: 2024 VS 2031
Figure 8. Solid Tumors Case Studies
Figure 9. Hematological Malignanciesncies Case Studies
Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Report Years Considered
Figure 11. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region: 2024 VS 2031
Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players in 2024
Figure 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024
Figure 17. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 19. United States Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 23. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2031)
Figure 31. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 39. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)
Figure 43. Turkey Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Lonza Group Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 47. Merck KGaA Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 48. WuXi XDC Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 49. Abbvie Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 50. Piramal Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 51. Catalent Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 52. Sterling Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 53. Axplora Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 54. Aji Bio-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 55. BSP Pharmaceuticals Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 56. Cerbios-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 57. Goodwin Biotechnology Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 58. TOT Biopharm Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 59. Huadong Medicine Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 60. Innovent Biologics Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 61. Shanghai Henlius Biotech Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232